Goldman Sachs analyst George Tong maintains Clarivate (NYSE:CLVT) with a Buy and lowers the price target from $8.5 to $7.5.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | Outperform → Mkt Perform | William Blair | |
| 12/15/2023 | $8.00 | Equal Weight → Underweight | Wells Fargo |
| 10/16/2023 | $10.00 → $8.50 | Hold → Buy | Jefferies |
| 9/8/2023 | $8.00 → $7.00 | Equal Weight → Underweight | Barclays |
| 8/25/2023 | $9.00 → $8.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/7/2023 | $10.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 8/4/2023 | $15.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 6/13/2023 | $11.00 | Outperform | Oppenheimer |
Concludes the appointments for business leaders of its three market segments LONDON, April 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today that it has appointed Henry Levy as President, Life Sciences & Healthcare, effective May 1, 2023. Henry joins from Veeva Systems, a global leader in cloud software for the life sciences industry, where he most recently served as President, Global R&D and Quality, with responsibility for driving sales across the segment. Jonathan Gear,
Appointing the second of three business leaders for its newly created market segments LONDON, April 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Bar Veinstein will join the company as President, Academia & Government, effective April 24, 2023. Bar joins from Taranis, an AI-powered crop intelligence provider, where he was Chief Executive Officer focusing on driving business growth, improving customer satisfaction and accelerating the company's artificial intelligence (AI) strategy. He previously spent 11 years with the Ex Libris Group, now part of Clarivate, and under his leader
Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
William Blair downgraded Clarivate from Outperform to Mkt Perform
Wells Fargo downgraded Clarivate from Equal Weight to Underweight and set a new price target of $8.00
Jefferies upgraded Clarivate from Hold to Buy and set a new price target of $8.50 from $10.00 previously
4 - CLARIVATE PLC (0001764046) (Issuer)
SC 13G - CLARIVATE PLC (0001764046) (Subject)
SC 13D/A - CLARIVATE PLC (0001764046) (Subject)
SC 13G/A - CLARIVATE PLC (0001764046) (Subject)
LONDON, Nov. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenues of $622.2 million decreased 3.9%Organic revenues decreased 2.6%, as an increase in subscription revenues of 0.6% was offset by a decrease in re-occurring revenues of 1.1% and transactional and other revenues of 13.6%Net loss of $65.6 million; Net loss per diluted share of $0.09Adjusted net income(1) of $134.1
LONDON, Oct. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the third quarter 2024 before the market opens on Wednesday, November 6, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Wednesday, November 6, 2024 to review the results. The webcast is open to all in
Chief Executive Jonathan Gear to Step Down as CEO and Member of the Board LONDON, Aug. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that the Board has appointed Matti Shem Tov, former CEO of ProQuest, as the Company's next CEO, effective August 9, 2024. Mr. Shem Tov will also join the Company's Board of Directors. Jonathan Gear, Chief Executive Officer, will step down as CEO and as a member of the Board at that time, and will transition into a non-executive role until November 1, 2024. "The Board
Rowan TELS Corp. is the provider of Rowan Patents – an integrated patent drafting and prosecution solution specially designed for patent practitioners to establish and protect patents more effectively.
These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Virtu Financial, Inc. (NASDAQ:VIRT) shares jumped 30.04% after reporting better-than-expected Q2 financial results. V.F. Corporation (NYSE:VFC) stock upped 22.38% after the company announced it entered into a Stock and Asset Purchase Agreement to sell its Supreme brand to EssilorLuxottica (OTC: ESLOF) for $1.5 billion in cash. Several analysts raised their price forecasts on VFC. New Fortress Energy Inc. (NASDAQ:NFE) shares grew 20.19% after the company announced that it achieved First LNG for its initial Fast LNG asset located offshore Altamira, Mexico. Riot Platforms Inc (NASDAQ:
Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a partnership with OhioLINK, Ohio's academic library consortium, and SearchOhio, a consortium of Ohio public libraries, to develop a new library resource sharing consortial experience. Through this partnership Clarivate will unify OhioLINK and SearchOhio's resource sharing platforms to enhance library user experiences and services, improve operational efficiencies and build upon existing consortia collaboration. The new solution is expected to be implemented by mid-year in 2025. The new solution will integrate OhioLINK and SearchOhio's existing INN-Reach platforms, part of Innovative™, i
10-Q - CLARIVATE PLC (0001764046) (Filer)
8-K - CLARIVATE PLC (0001764046) (Filer)
8-K - CLARIVATE PLC (0001764046) (Filer)
New seven-part series explores disparities in care, funding and innovation impacting half the world's population LONDON, Nov. 21, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide.' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment. Women make up half of the global population, yet their health remains consistently underserved. Research and treatments have traditionally fo
Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON, Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,636 Highly Cited Researche
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come. Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, rankin